






































Besides	 their	 well‐described	 use	 as	 delivery	 systems	 for	 water‐soluble	 drugs,	35	
liposomes	 have	 the	 ability	 to	 act	 as	 a	 solubilizing	 agent	 for	 drugs	 with	 low	36	
aqueous	solubility.	However,	a	key	limitation	in	exploiting	liposome	technology	37	
is	the	availability	of	scalable,	low‐cost	production	methods	for	the	preparation	of	38	
liposomes.	 Here	 we	 describe	 a	 new	 method,	 using	 microfluidics,	 to	 prepare	39	
liposomal	 solubilising	 systems	 which	 can	 incorporate	 low	 solubility	 drugs	 (in	40	
this	case	propofol).		The	setup,	based	on	a	chaotic	advection	micromixer,	showed	41	
high	drug	 loading	 (41	mol%)	of	 propofol	 as	well	 as	 the	 ability	 to	manufacture	42	
vesicles	with	at	prescribed	sizes	(between	50	to	450	nm)	 in	a	high‐throughput	43	
setting.	Our	results	demonstrate	the	ability	of	merging	liposome	manufacturing	44	







The	 delivery	 of	 drugs	 by	 liposomes	 was	 first	 described	 in	 the	 1970s	 by	50	
Gregoriadis	(Gregoriadis	and	Ryman,	1971)	and	there	is	now	a	range	of	clinically	51	





issues	 in	 bioavailability	 (Savjani	 et	 al.,	 2012;	 Williams	 et	 al.,	 2012).	 The	57	
encapsulation	 of	 low	 solubility	 drugs	 into	 the	 bilayer	 of	 liposomes	 allows	 not	58	
only	 for	 their	 solubilisation	 in	 an	 aqueous	 media,	 but	 furthermore	 can	 offer	59	
protection	 from	 degradation	 and	 control	 over	 the	 pharmacokinetic	 drug	60	
distribution	profile	and	improved	therapeutic	efficacy.		61	
	62	
When	 solubilising	 drug	 within	 the	 liposomal	 bilayer,	 drug	 incorporation	 and	63	
release	 rates	 has	 been	 shown	 to	 depend	 on	 the	 properties	 of	 the	 drug,	 the	64	
composition	of	the	liposomes,	the	lipid	choice	and	concentration	(Ali	et	al.,	2010;	65	
Ali	et	al.,	2013;	Mohammed	et	al.,	2004).	For	example,	 the	 log	P	and	molecular	66	
weight	 are	 often	 considered	 to	 impact	 on	 bilayer	 loading,	 and	 studies	 have	67	
shown	that	molecular	weight	may	play	a	dominant	role	(Ali	et	al.,	2013).	When	68	
considering	the	design	of	liposomes,	there	are	a	range	of	parameters	that	impact	69	
on	 bilayer	 loading	 efficacy.	 	 For	 example,	 we	 have	 previously	 shown	 that	70	
increasing	 the	 bilayer	 lipophillic	 volume	 (by	 adopting	 longer	 alkyl	 chain	 lipids	71	
within	 the	 liposomes)	 increases	 the	 loading	 ability	 of	 liposomal	 systems	72	
(Mohammed	 et	 al.,	 2004;	 Ali	 et	 al.,	 2013).	 	 Similarly,	 incorporation	 of	 charged	73	
lipids	within	 the	 liposomal	 system	may	also	 impact	on	bilayer	 loading	 through	74	
electrostatic	 repulsion	 of	 drugs	 with	 like‐charged	 liposomal	 bilayers	75	








(when	 no	 cholesterol	 was	 present)	 to	 first	 order	 (when	 11	 to	 33	 mol%	 of	82	
cholesterol	was	 incorporated).	 	 This	maps	 to	 the	 idea	 that	without	 cholesterol	83	
the	bilayer	can	be	thought	of	as	more	‘porous’	in	nature	compared	with	the	more	84	





required	 into	 making	 liposomes	 a	 cost‐effective	 solubilising	 agent.	 Recent	90	
advances	in	lab‐on‐a‐chip	based	tools	for	process	development	has	already	lead	91	





controlled	 alterations	 in	 polarities	 throughout	 the	 mixer	 chamber,	 which	 is	97	
followed	 by	 a	 nanoprecipitation	 reaction	 and	 the	 self‐assembly	 of	 the	 lipid	98	
molecules	into	liposomes.	Generally,	two	or	more	inlet	streams	(lipids	in	solvent	99	
and	 an	 aqueous	 phase)	 are	 rapidly	 mixed	 together	 and	 flow	 profiles	 in	 the	100	
chamber	 itself	 are	of	 low	Reynolds	numbers	and	categorized	as	 laminar.	Using	101	
microfluidic	 systems	 a	 tight	 control	 of	 the	 mixing	 rates	 and	 ratio	 between	102	
aqueous	 and	 solvent	 streams	 is	 achieved,	with	 lower	 liquid	 volumes	 required,	103	
which	facilitates	process	development	by	reducing	time	and	development	costs.	104	
The	systems	are	designed	with	the	option	of	high‐throughput	manufacturing	and	105	
are	 generally	 considered	 as	 less	 harsh	 compared	 to	 conventional	 methods	 of	106	
liposome	 manufacturing	 that	 are	 based	 on	 mechanical	 disruption	 of	 large	107	
vesicles	 into	 small	 and	 unilamellar	 ones	 (Wagner	 and	 Vorauer‐Uhl,	 2011).	108	
Within	 the	 range	 of	 microfluidic	 mixing	 devices,	 we	 use	 a	 chaotic	 advection	109	
micromixer,	a	Staggered	Herringbone	Micromixer	(SHM).	The	fluid	streams	are	110	






Jahn	 et	 al.,	 2007).	 The	 method	 based	 on	 chaotic	 advection	 was	 shown	 to	115	
reproducibly	 generate	 small	 unilamellar	 liposomes	 (SUV)	with	 tight	 control	 of	116	
the	resulting	liposome	sizes	at	flow	rates	as	high	as	70	mL/min	in	a	parallelized	117	
mixer‐setup.	 We	 have	 previously	 shown	 that	 microfluidics	 can	 be	 used	 to	118	
produce	 cationic	 liposomal	 transfection	 agents	 (Kastner	 et	 al.,	 2014),	 where	119	
design	 of	 experiments	 and	 multivariate	 analysis	 revealed	 the	 ratio	 between	120	
aqueous	and	solvent	phase	having	a	strong	relevance	for	the	formation	of	size‐121	
controlled	 liposomes.	 Within	 this	 study,	 we	 have	 exploited	 microfluidics	 to	122	





Figure	 1:	 Schematic	 depiction	 of	 the	 liposome	 formation	 process	 based	 on	 the	128	















Company	 Ltd.,	 Poole,	 UK.	 Ethanol	 and	 methanol	 were	 obtained	 from	 Fisher	140	
Scientific	 UK,	 Loughborough,	 UK.	 TRIS	 Ultra	 Pure	 was	 obtained	 from	 ICN	141	





The	 micromixer	 was	 obtained	 from	 Precision	 NanoSystems	 Inc.,	 Vancouver,	147	
Canada.	 The	mixer	 contained	moulded	 channels	which	were	 200	 µm	 x	 79	 µm	148	
(width	 x	 height)	 with	 herringbone	 features	 of	 50	 x	 31	 µm.	 1	 mL	 disposable	149	
syringes	were	used	for	the	inlet	streams,	with	respective	fluid	connectors	to	the	150	
chip	 inlets.	 	Formulations	 using	 the	 micromixer	 were	 performed	 on	 a	151	
NanoAssemblr™	(Precision	NanoSystems	 Inc.,	Vancouver,	Canada)	 that	allowed	152	
for	 control	of	 the	 flow	rates	 (0.5	 to	6	mL/min)	and	 the	 flow	ratios	 (1:1	 to	1:5,	153	
ratio	between	solvent:aqueous)	between	the	respective	streams.	154	
2.3 Formulation of small unilamellar vesicles using microfluidics 155	
Lipids	 (16:4	 molar	 ratio	 of	 PC	 and	 Cholesterol,	 8:1	 w/w)	 were	 dissolved	 in	156	
ethanol.	SUV	were	manufactured	by	injecting	the	lipids	and	aqueous	buffer	(TRIS	157	












its	 low	 molecular	 weight	 (Ali	 et	 al.,	 2013).	 To	 encapsulate	 propofol,	 the	 low	168	
solubility	 drug	 was	 dissolved	 with	 the	 lipids	 in	 ethanol	 (0.5	 to	 3mg/mL)	 and	169	




Multilamellar	 vesicles	 (MLV)	 were	 prepared	 using	 the	 lipid	 film	 hydration	174	
method	 (Bangham	 et	 al.,	 1965).	 Basically,	 lipids	 were	 dissolved	 in	175	
chloroform/methanol	 (9:1	 v/v)	 and	 the	 organic	 solvent	 was	 subsequently	176	
removed	by	rotary	evaporation	under	vacuum	to	form	a	dry	lipid	film	which	was	177	





Characterisation	 of	 the	 liposomes	 included	 size	 measurements	 using	 dynamic	183	
light	 scattering	 (DLS)	 (Malvern	 NanoZS),	 reported	 as	 the	 z‐average	 (intensity	184	









to	 100%	 B	 over	 10	 minutes.	 HPLC‐grade	 liquids	 were	 used,	 sonicated	 and	194	
filtered.	The	column	temperature	was	controlled	at	35ºC.	All	analysis	was	made	195	
in	Clarity,	DataApex	version	4.0.3.876.	Quantification	was	achieved	by	reference	196	








The	amount	of	drug	 loaded	 into	 the	bilayer	was	measured	by	determination	of	203	
the	 residual	 amount	 of	 drug	 in	 the	 liposome	 bilayer	 after	 removal	 of	 non‐204	
entrapped	drug	by	dialysis	(sink	conditions)	against	1	L	of	TRIS	buffer,	10mM	pH	205	
7.2	 (3500	 Da,	 Medicell	 Membranes	 Ltd.,	 London,	 UK).	 The	 drug	 content	 was	206	





25°C	 and	 40°C	 in	 pharmaceutical	 grade	 stability	 cabinets	 over	 60	 days	 (time	212	
point	measurements	at	day	0,	7,	14,	21,	28	and	60).	Samples	were	taken	at	these	213	
specific	time	points	for	measurement	of	particle	characteristics	(section	2.5)	and	214	
drug	 loading	 (section	 2.6).	 Samples	were	 dialysed	 against	 500	mL	TRIS	 buffer	215	






amount	 of	 lipid	 and	 propofol	 was	 measured	 by	 HPLC	 and	 expressed	 as	 %	222	























The	 in‐vitro	 release	 rate	 of	 the	 drug	 was	 determined	 by	 incubating	 the	 drug‐244	
loaded	 liposomes	 in	1	L	TRIS	buffer	 (10mM,	pH	7.2)	after	 removal	of	 the	non‐245	
incorporated	 drug,	 at	 37°C	 in	 a	 shaking	 water	 bath	 (150	 shakes/min).	 Three	246	
independent	 formulations	 of	 drug‐loaded	 liposomes	made	by	 the	microfluidics	247	
method	(TFR	2	mL/min,	FRR	1:3)	and	standard	lipid	film	hydration	followed	by	248	
sonication	were	incubated	(3	mL	per	formulation)	and	samples	of	200	µL	were	249	
withdrawn	 at	 time	 intervals	 of	 0.5	 h,	 1	 h,	 2	 h,	 4	 h,	 8	 h	 and	 16	 h.	 Drug	250	





the	 nanoparticles	 manufactured	 was	 verified	 by	 including	 and	 imaging	 of	 an	256	
aqueous	fluorescent	dye.	Liposomes	were	manufactured	as	described	in	section	257	
2.3	and	2.4	with	1	mM	Carboxyfluorescein	(CF)	 included	 in	 the	aqueous	buffer	258	
(TRIS,	10	mM,	pH	7.2).	Liposomes	with	entrapped	CF	were	separated	from	un‐259	
entrapped	 dye	 by	 dialysis	 over	 night	 against	 1	 L	 fresh	 TRIS	 buffer,	 pH	 7.2.	260	
Liposomes	 were	 imaged	 under	 a	 confocal	 microscope	 SP5	 TCS	 II	 MP,	 Leica	261	
10	
	





One‐	 or	 two‐way	 analysis	 of	 variance	 (ANOVA)	 was	 used	 to	 assess	 statistical	267	
significance,	 followed	 by	 Tukeys	 multiple	 comparing	 test	 and	 t‐test	 was	268	
performed	for	paired	comparisons.	Significance	was	acknowledged	for	p	values	269	




3.1 Influence  of  the  flow  rate  ratio  of  aqueous  and  solvent  stream  on 274	
liposome size 275	
The	 increase	 in	polarity	 throughout	 the	chamber	drives	 the	 formation	of	 small	276	
unilamellar	 liposomes	(SUV)	 in	milliseconds	of	mixing.	For	 their	 formation,	 the	277	
rate	 of	 mixing	 as	 well	 as	 the	 ratio	 of	 aqueous	 to	 solvent	 stream	 has	 been	278	




assess	 the	 efficacy	 of	 this	 system	 to	 act	 as	 a	 solubilising	 agent.	 Therefore,	283	
liposomes	were	prepared	from	PC	and	Cholesterol	(16:4	molar	ratio,	8:1	w/w)	at	284	











agreement	 with	 average	 vesicle	 diameters	 obtained	 by	 particle	 sizing	 via	294	
dynamic	 light	 scattering	 (~40	 nm).	 In	 contrast,	 the	 smallest	 vesicle	 size	 of	 a	295	
comparable	 formulation	 achievable	 via	 probe	 sonication	 with	 this	 lipid	296	
formulation	was	100	nm	 in	 size	 at	PDIs	of	0.3	 (data	not	 shown).	To	verify	 the	297	
















Figure	2:	 Liposome	 size	 (A)	 and	polydispersity	 (B)	of	 vesicles	 formulated	with	309	
microfluidics	method	 at	 increasing	 flow	 ratios.	 ns	 =	 not	 significant	 (p>0.05),	 *	310	
denotes	 statistical	 significance	 (p<0.05)	 in	 comparison	 to	 FRR	 1:1	 	 (C)	 Freeze	311	
fracturing	electron	microscopy	 images	for	empty	 liposomes	manufactured	with	312	
the	microfluidics	method.	 Bar	 represents	 100	 nm.	 (D)	 Fluorescent	microscope	313	






These	 impact	of	 flow	 rate	 ratio	on	vesicle	 size	 are	 in	agreement	with	previous	320	
work	 showing	 that	 the	 increase	 in	 FRR	 reduces	 the	 resulting	 size	 of	 the	321	
liposomes	 (Jahn	et	 al.,	 2010;	Kastner	et	 al.,	 2014;	Zook	and	Vreeland,	2010).	A	322	
correlation	between	higher	 flow	rate	 ratios	and	smaller	 liposome	particles	has	323	
been	 reported	 using	 liposomes	 composed	 of	 1‐palmitoyl,	 2‐oleoyl	324	
phosphatidylcholine	 (POPC),	 cholesterol	 and	 the	 triglyceride	 triolein,	 which	325	
resulted	 in	 the	 production	 of	 vesicular	 structures	with	 sizes	 ranging	 from	140	326	
nm	to	40	nm	dependent	on	the	FRR	chosen	and	triglyceride	emulsions	between	327	
20−	50	nm	size	with	nonpolar	cores	(Zhigaltsev	et	al.,	2012).	The	overall	 lower	328	
amount	 of	 residual	 solvent	 present	 at	 higher	 FRR	 employed	 decreases	 the	329	




manufacturing	 (Kastner	 et	 al.,	 2014).	With	 diffusion	 being	 proportional	 to	 the	334	
lipid	 concentration,	 increasing	 FRR	 is	 effectively	 reducing	 the	 lipid	335	
concentration,	 thus	 reducing	 the	 rate	 of	 diffusion,	 leading	 to	partly	 incomplete	336	
nucleation	 and	 a	 lower	 rate	 of	 liposome	 formation	 inside	 the	 micromixer	337	
(Balbino	et	al.,	2013b).	Overall,	 these	findings	demonstrate	that	a	FRR	of	1:2	to	338	
1:4	result	in	liposomes	of	the	smallest	size	and	polydispersity.	The	dilution	factor	339	





method	 enhances	 the	 diffusional	mixing	 due	 to	 the	 herringbone	 structures	 on	343	
















suggested	 by	 Belliveau	 et	 al.	 2013,	 by	 parallelization	 of	 the	 mixer	 chamber.	360	

















Ray,	 2009),	 chromatography	 (Ruysschaert	 et	 al.,	 2005)	 or	 centrifugation	 adds	376	
additional	processing	time.	Therefore,	to	circumvent	this	additional	process	step,	377	
we	counteracted	the	dilution	of	the	lipids	at	higher	FRR	by	increasing	initial	lipid	378	
concentrations	 introduced	 to	 the	micromixer	 at	 the	 desired	 FRR.	Through	 this	379	
method,	 liposomes	 were	 manufactured	 at	 up	 to	 6	 fold	 higher	 concentrations.	380	
Increased	 lipid	 concentrations	 at	 FRR	 of	 1:3	 and	 1:5	 did	 not	 significantly	381	
(p>0.05)	 influence	 size	 and	 polydispersity	 compared	 to	 the	 standard	 lipid	382	
concentration	(Figure	4A	and	B),	whereas	at	a	FRR	of	1:1	a	significant	(p<0.05)	383	
decrease	in	vesicle	size	was	observed	(Figure	4A).	At	this	lower	FRR,	the	higher	384	
lipid	 concentrations	 may	 again	 decreasing	 particle	 fusion	 leading	 to	 the	385	
formation	of	 smaller	particles	 (Zhigaltsev	et	al.,	2012).	Nevertheless,	 this	setup	386	
allows	to	increase	the	final	liposome	concentration	according	to	the	FRR	chosen	387	


























































































































































































polydispersity	 (Figure	 5A).	 	 Particle	 size	 and	 polydispersity	 increased	 notably	419	
(ca.	 600	 nm	 and	 0.8	 respectively)	 at	 the	 highest	 propofol	 concentration	 (3	420	
mg/mL	 in	 the	 solvent	 stream,	 giving	 a	 loading	 of	 ~25mol%,	 Figure	 5A),	421	





The	 drug	 encapsulation	 was	 further	 investigated	 as	 a	 function	 of	 FRR	 in	 the	427	
microfluidics	method.	Propofol	encapsulation	(mol%)	 in	 liposomes	prepared	at	428	
FRR	 1:1,	 1:3	 and	 1:5	 remained	 at	 approximately	 50	 mol%	 with	 no	 statistical	429	
difference.	However	this	was	significantly	higher	(p<	0.0001)	than	drug	loading	430	
in	 liposomes	 prepared	 via	 sonication	 (15	mol%;	 Figure	 5B).	 The	 drug	 loading	431	
efficiency	of	liposomes	prepared	by	sonication	is	in	line	with	previous	reported	432	
propofol	 encapsulation	 (Ali	 et	 al.,	 2013).	 Furthermore,	 drug	 encapsulation	 did	433	
not	alter	vesicle	size	or	polydispersity	(Figure	5A)	and	vesicle	sizes	obtained	by	434	
dynamic	 light	 scattering	were	verified	by	 freeze	 fracturing	 images	 (Figure	5D).	435	
This	higher	drug	loading	may	be	a	result	of	the	highly	efficient	mixing	processes	436	
occurring	during	microfluidics	that	favours	incorporation	of	propofol	within	the	437	
bilayers	 in	 the	 same	 process	 as	 the	 vesicles	 form.	 Indeed,	 the	 here	 presented	438	
method	 allows	 to	 achieve	 a	 propofol	 encapsulation	 of	 ~50	 mol%,	 which	439	
represents	 a	 total	 propofol	 amount	 of	 ~300	 mg/mL	 in	 the	 final	 liposome	440	




























triplicate	 formulations	 and	 measurements.	 ns	 =	 not	 significant	 (p>0.05),	 *	459	














start	 of	 the	 release	 study	 (~55	mol%)	 compared	 to	 those	 vesicles	 formed	 by	472	
sonication	(20	mol%	drug	encapsulation).	However,	relative	to	initial	loading,	an	473	
initial	release	of	ca	40%	was	observed	at	1	h	for	both	formulations,	followed	by	a	474	
continuous	 release	 of	 90%	 of	 the	 encapsulated	 drug	 was	 observed	 over	 8	 h	475	
(Figure	6).	Whereas	the	fatty	alcohol	alkyl	chain	length	was	shown	to	affect	the	476	
release	 profile	 of	 encapsulated	 propofol	 (Ali	 et	 al.,	 2013),  here	 the	 method	 of	477	
liposome	 manufacturing	 was	 shown	 to	 mainly	 affect	 the	 amount	 of	 drug	478	
incorporated	 into	 the	 liposomes,	 without	 altering	 the	 release	 profile	 of	 the	479	
encapsulated	 drug	 against	 sink	 conditions.	 Previous	 we	 have	 shown	 that	480	
solubilisation	 of	 propofol	 in	 phosphatidylcholine	 liposomes	 followed	 a	 zero‐481	
order	release	kinetics,	where	the	incorporation	of	a	higher	amount	of	cholesterol	482	
shifted	 the	 release	 rates	 towards	 a	 first‐order	 release	model	 (Ali	 et	 al.,	 2010),	483	
implying	 that	 the	 release	 kinetics	 itself	 are	 mainly	 dominated	 by	 the	 lipid	484	




rapid	distribution	of	propofol	 compared	 to	 the	 commercial	product	Diprivan®	489	










Figure	6:	 Effect	 of	manufacturing	method	 to	 the	drug	 release	of	 propofol	 from	498	
liposomes.	Results	show	the	cumulative	drug	release	profile	 from	formulations	499	




It	 is	 important	 to	 verify	 both	 lipid	 and	 drug	 recovery	 when	 using	 the	504	
microfluidics	 method,	 to	 ensure	 cost‐effectiveness	 and	 that	 lipid	 and	 drug	505	
concentrations	remain	locked	at	the	ratio	initially	designed	prior	to	formulation.	506	
To	date,	the	quantification	of	lipids	is	mainly	dominated	by	time	intensive	assays	507	
like	mass	 spectrometry	 (Moore	 et	 al.,	 2007).	 Here,	we	 introduce	 a	 simple	 and	508	
robust	method	of	lipid	quantification	based	on	evaporative	light	scattering	(ELS)	509	
detection	and	HPLC	separation.	We	coupled	an	ELS	detector	downstream	a	HPLC	510	
separation	method,	which	allowed	 for	quantification	of	any	solids	 in	 the	eluate	511	
with	a	lower	volatility	than	the	mobile	phase.	Microfluidics	based	liposomal‐drug	512	












3.4 The  effect of manufacturing methods on  liposome  stability  and drug 523	
encapsulation over 8 weeks  524	




course	of	 eight	weeks	 (Zhigaltsev	et	 al.,	 2012).	 	 Following	 the	 assessment	 that	529	




propofol	 encapsulated	 was	 determined	 after	 removal	 of	 free	 drug	 by	 dialysis.	534	
Vesicles	 were	 stored	 at	 4°C,	 25°C/60%RH	 and	 40°C/75%RH	 (standard	 ICH	535	
temperatures)	 in	 pharmaceutical	 grade	 stability	 cabinets	 and	 the	 formulations	536	
made	by	the	sonication	method	were	stored	at	25°C/60%RH	(Figure	7,	Table	1),	537	
acting	 as	 the	 control	 method.	 The	 control	 liposomes	 formed	 by	 sonication	538	
showed	 good	 stability	 in	 terms	 of	 size	 retention	 over	 the	 course	 of	 the	 study.	539	
Similarly,	 for	 liposomes	 prepared	 using	 microfluidics,	 vesicle	 size	 remained		540	
unaffected	 after	 storage	 over	 8	weeks	 at	 4°C	 and	 25°C.	 In	 contrast,	 liposomes	541	
stored	 at	 40°C	 significantly	 increase	 in	 size	 from	 initially	 55	 nm	 to	 120	 nm	542	
(Figure	 7A),	 with	 no	 notable	 affect	 to	 polydispersity,	 suggesting	 the	 liposome	543	




Table	1:	Polydispersity	 at	different	 storage	 conditions	 for	8	weeks.	Results	 are	548	
mean	out	of	triplicate	formulations	and	measurements.	549	
Day	 0	 7	 14 21 28 60	
Microfluidics	 	 	 	
4°C		 0.403	±	0.02	 0.286	±	0.01 0.282	±	0.01	 0.295	±	0.01 0.261	±	0.01	 0.	305	±	0.01
21	
	
25°C		 0.403	±	0.02	 0.295	±	0.01 0.279	±	0.01 0.301	±	0.04 0.302	±	0.03	 0.266	±	0.03
40°C	 0.403	± 0.02	 0.254	±	0.001 0.121	±	0.02 0.119	±	0.001 0.129	±	0.01	 0.221	±	0.01
Sonication	 	 	 	
25°C		 0.656	±	0.02	 0.652	±	0.02 0.522	±	0.15 0.658	±	0.049 0.552	±	0.04	 0.505	±	0.06
	550	
Figure	 7:	 Size	 (A)	 and	 drug	 encapsulation	 (mol%)	 (B)	 at	 different	 storage	551	
conditions	 over	 8	 weeks.	 Results	 are	 mean	 of	 triplicate	 formulations	 and	552	
measurements.	553	
	554	
Minor	 (but	 not	 significant)	 drug	 loss	 from	 the	 liposomes	was	 detected	 for	 the	555	
formulations	at	4°C	and	25°C	after	 the	 first	7	days	of	storage	(Figure	7B),	after	556	
which	the	formulations	remained	stable	with	final	drug	encapsulation	values	of	557	




were	 stored	 at	 elevated	 temperatures	 with	 the	 formulation	 stored	 at	 40°C	562	
showing	almost	 complete	drug	 loss	over	 the	 course	of	 the	 stability	 study,	with	563	
only	5±1	mol%	drug	remaining	encapsulated	after	8	weeks,	similar	 to	 the	 final	564	
drug	 encapsulated	 in	 the	 sonicated	 liposomes	 which	 were	 stored	 at	565	
25°C/60%RH	 (Figure	 7B).	 Overall,	 vesicles	 produced	 with	 the	 microfluidics	566	
method	were	 smaller	with	 a	 lower	polydispersity	 than	 those	obtained	by	 lipid	567	
film	hydration	/	sonication.	The	vesicles	manufactured	by	sonication	maintained	568	
their	size	around	100±20	nm	throughout	the	stability	study	(stored	at	25°C)	as	569	
well	 as	 their	 polydispersity	 (Table	 1).	 Results	 suggest	 that	 the	 method	 of	570	
22	
	
manufacturing	mainly	 impacts	 the	drug	encapsulation	 rather	 than	 the	physical	571	
properties	(size,	pdi,	zeta	potential).	Stability	of	 the	 formulations	 is	crucial	and	572	






These	 liposomes	 have	 well	 defined,	 scalable,	 process	 controlled,	 physico‐579	
chemical	 attributes	 demonstrating	 this	 method	 is	 suitable	 for	 pre‐clinical	 and	580	
clinical	production	of	liposomes.	Drug	loading	was	shown	to	be	in	an	applicable	581	
range	 for	 clinical	 application	 (Biebuyck	 et	 al.,	 1994).	 Furthermore,	 using	 this	582	
novel	method,	liposome	manufacturing	and	drug	encapsulation	are	processed	in	583	
a	 single	 process	 step,	 circumventing	 an	 additional	 drug	 loading	 step	584	
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